Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

since the commencement of the grant in July 2005.

Research and development expenses for the three months ended June 30, 2008 and 2007 were $9.2 million and $10.5 million, respectively. Research and development expenses for the six months ended June 30, 2008 and 2007 were $20.6 million and $20.5 million, respectively. The decrease of $1.3 million for the three month period was primarily attributable to a decrease in preclinical and clinical costs incurred in connection with the research and development activities of our oncology pipeline. Research and development expenses for the six month periods were generally consistent from period to period.

General and administrative expenses for the three months ended June 30, 2008 and 2007 were $2.3 million and $2.1 million, respectively. General and administrative expenses for the six months ended June 30, 2008 and 2007 were $4.4 million in each period. The increase of $0.2 million for the three month period was primarily attributable to an increase in legal and professional fees offset by a decrease in share-based compensation expense.

SGX reported a net loss for the three months ended June 30, 2008 of $7.2 million, or $0.35 per share. This compares with a net loss for the three months ended June 30, 2007 of $4.0 million, or $0.26 per share. For the six months ended June 30, 2008, the net loss was $3.5 million, or $0.17 per share. This compares with a net loss for the six months ended June 30, 2007 of $5.1 million, or $0.33 per share. The net loss for the six months ended June 30, 2008 is less than the net loss for the three months ended June 30, 2008 due to the Company's reporting net income in the first quarter of 2008 as a result of the $10.8 million of revenue earned in the first quarter that was attributable to the one-time recognition of the remaining portion of the upfront payment related to the Company's collaboration with Novartis.

About SGX Pharmaceuticals

SGX Pharmaceuticals, Inc
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Sales Horizons, a leader in sales ... training programs for companies engaged in complex B2B sales. ... thousands of salespeople over 25 years in market-leading Fortune ... be customized to address the unique sales challenges of ... training program consists of two parts: Mastering the ...
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... 7, 2011 Reportlinker.com announces that a new ... Industrial Biotechnology China News 1103 ... The Chinese central government was reported to continue ... the Twelfth Five-Year (2011-2015) Plan. This act is ...
... and industrial research scientists and engineers, as well ... encounter a steep learning curve when developing common ... book just published by Springer promises to be ... The new MEMS Materials and Processes Handbook is ...
... The U.S. Food and Drug Administration today approved ... tool to treat brain aneurysms without performing open surgery. ... An aneurysm is a weak, enlarged area in an ... blood pressure can cause it to rupture, which can ...
Cached Biology Technology:Reportlinker Adds Industrial Biotechnology China News 1103 2Reportlinker Adds Industrial Biotechnology China News 1103 3MEMS Materials and Processes Handbook -- a comprehensive, practical resource 2FDA Approves New Device to Treat Brain Aneurysms 2FDA Approves New Device to Treat Brain Aneurysms 3
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... State University,s College of Engineering recently received a ... the project, "Nanoparticle-directed synthesis of organic nanorods." ... is the creation and utilization of functional materials, ... A major bottleneck in scaling up nanotechnology is ... functional materials into one device. A research team ...
(Date:7/30/2014)... into a multitude of cells types. Researchers would like to ... of mature cells that make up the organs and other ... be long chains of sugars that dangle from proteins on ... of California, San Diego, has created synthetic molecules that can ... easily manipulated to direct the process, they report in the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... , This news release is available ... Medical implants, complex interfaces between brain and machine or ... great potentials, but also give rise to major ethical concerns. ... technischer Systeme mit Lebewesen" (The Chemistry of Cyborgs Interfacing ...
... cells scientists at Brigham and Women,s Hospital and MIT ... following transplantation, potentially making cell therapies, hundreds of which ... more functional and efficient. Associate Professor Jeffrey Karp, ... issue of Nature Protocols how to load ...
... , Jan. 10, 2014   BioNano Genomics announced today ... present at the 32nd Annual J.P. Morgan Healthcare Conference in ... p.m. PST.  About BioNano Genomics ... delivering an altogether better way of gaining a fully informed understanding ...
Cached Biology News:The cyborgs era has started 2The cyborgs era has started 3Harvard scientists control cells following transplantation, from the inside out 2
... Gene Expression (SAGE) is a powerful ... a cost-effective outsourcing solution for sequencing ... Agencourt's SAGE sequencing service provides our ... long Phred20 read lengths (40 SAGE ...
... Sciences can provide custom microplate coating using advanced automated high ... of plate formats. We can also accommodate virtually any lot ... 0.5-320 L):, , 8 ... well microplate, 384 well microplate, ...
... ) The antibody is preadsorbed to remove any ... buffered aqueous glycerol solution A solution ... 2+ and Ca 2+ ), pH 7.3 ... (IgG, protease free) and 0.05% sodium azide A ...
... Cytometry The Guava EasyCyte system is ... multiparameter cytometer with built-in 96-well microplate sampling ... plates of cells and compounds quickly and ... tubes or having the carryover issues found ...
Biology Products: